Alkermes plc Ordinary Shares
Exchange: NASDAQ
Symbol: ALKS
SEC CIK: 0001520262
Phone: 00-353-1-772-8000
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN 4 L2 00000
CEO:
|
Price when page updated: 24.06 Date: 2023-11-30
Company Website:
www.alkermes.com
|
_Description: Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
IPO YEAR:
1991
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
4015163741.00
|
Beta:
0.725781131330879
|
52 Week High:
33
|
52 Week Low:
18.02
|
52 Week Change:
0.1225535880708295
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
161705367
|
Dividend Rate:
0
|
Dividend Yield:
N/A
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
26 Oct 2022
|
Float:
0
|
return on Equity:
-8.60%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
-$1.73
|
ttmEPS:
-0.5693
|
Revenue:
$1.173B
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
99.50%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
1.10%
|
Return on Assets:
-4.70%
|
Return on Capital:
|
Profit Margin:
-8.00%
|
Price to Sales:
3.68
|
Price To Book:
3.96
|
Short Ratio:
4.91
|
PE Ratio:
-42.48813632727629
|
Employees:
2245
|
1Y Guesstimate
28.810:1.0:6
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Alkermes plc Ordinary Shares [ ALKS ].
__Note: Some Links might not have information for the company.
|
|
